poisar

Stocks · News reference

RBC Capital Maintains Outperform on Charles River, Raises Price Target to $282

Benzinga Newsdesk

RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $215 to $282.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CRL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Bcc Research

    Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic Innovation

    The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

    DGXLHCRLSKHHYERRFY
  2. Zacks.Com

    Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

    RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.

    RSPHVHTXLVCRLVEEV
  3. Researchandmarkets.Com

    Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific

    The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.

    CRLLHERRFY
  4. Researchandmarkets.Com

    Large Molecule Bioanalytical Testing Services Global Market Report 2026-2035 | Identify High-Growth Opportunities and Develop Informed Commercial Strategies

    The global large molecule bioanalytical testing services market is projected to grow from USD 3.11 billion in 2026 to USD 5.88 billion by 2035, with a CAGR of 7.3%. Growth is driven by increasing biologics pipelines, demand for personalized therapies, and outsourcing to CROs and CDMOs. Pharmacokinetics testing dominates at 45% of market revenue, while bioequivalence testing is expected to grow fastest. North America leads with 50% of global revenue, while Asia-Pacific is the fastest-growing region at 8.6% CAGR.

    CRLERRFYWUXAYSGSOY